NCT05621759View on ClinicalTrials.gov

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 7, 2022

Primary Completion Date

August 23, 2025

Study Completion Date

August 23, 2026

Conditions
Graft Vs Host Disease
Interventions
DRUG

Cyclophosphamide

Nitrogen mustard alkylating agent produced by Bristol-Myers Squibb.

DRUG

Abatacept

Calcineurin-inhibitor produced by Astellas.

DRUG

Tacrolimus

Selective T cell co-stimulation modulator produced by Bristol-Myers Squibb.

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER